Literature DB >> 20810181

Bacteriophages as potential new therapeutics to replace or supplement antibiotics.

Mzia Kutateladze1, Revaz Adamia.   

Abstract

Over recent decades, a growing body of literature has validated the use of bacteriophages for therapy and prophylaxis in the war against drug-resistant bacteria. Today, much more is known about bacteriophages than in the 1930s when phage therapy first appeared and began to spread to many countries. With rapid dissemination of multi-drug-resistant bacterial pathogens, the interest in alternative remedies to antibiotics, including bacteriophage treatments, is gaining new ground. Based on recent experience and current results of bacteriophage applications against bacterial infections in countries where this alternative therapy is approved, many scientists and companies have come to believe that the use of phages for treating and preventing bacterial diseases will be successful.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20810181     DOI: 10.1016/j.tibtech.2010.08.001

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  124 in total

1.  Impact of relative humidity and collection media on mycobacteriophage D29 aerosol.

Authors:  Keyang Liu; Zhanbo Wen; Na Li; Wenhui Yang; Jie Wang; Lingfei Hu; Xiaokai Dong; Jianchun Lu; Jinsong Li
Journal:  Appl Environ Microbiol       Date:  2011-12-22       Impact factor: 4.792

2.  Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

Authors:  Isabelle Huys; Jean-Paul Pirnay; Rob Lavigne; Serge Jennes; Daniel De Vos; Minne Casteels; Gilbert Verbeken
Journal:  EMBO Rep       Date:  2013-10-18       Impact factor: 8.807

Review 3.  Bacteriophage orphan DNA methyltransferases: insights from their bacterial origin, function, and occurrence.

Authors:  James Murphy; Jennifer Mahony; Stuart Ainsworth; Arjen Nauta; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2013-10-11       Impact factor: 4.792

4.  Experience of the Eliava Institute in bacteriophage therapy.

Authors:  Mzia Kutateladze
Journal:  Virol Sin       Date:  2015-02       Impact factor: 4.327

5.  Two Phages, phiIPLA-RODI and phiIPLA-C1C, Lyse Mono- and Dual-Species Staphylococcal Biofilms.

Authors:  Diana Gutiérrez; Dieter Vandenheuvel; Beatriz Martínez; Ana Rodríguez; Rob Lavigne; Pilar García
Journal:  Appl Environ Microbiol       Date:  2015-03-06       Impact factor: 4.792

Review 6.  Veterinary pharmaceuticals in aqueous systems and associated effects: an update.

Authors:  Samuel Obimakinde; Olalekan Fatoki; Beatrice Opeolu; Olatunde Olatunji
Journal:  Environ Sci Pollut Res Int       Date:  2016-10-18       Impact factor: 4.223

7.  Characterization and genome sequencing of phage Abp1, a new phiKMV-like virus infecting multidrug-resistant Acinetobacter baumannii.

Authors:  Guangtao Huang; Shuai Le; Yizhi Peng; Yan Zhao; Supeng Yin; Lin Zhang; Xinyue Yao; Yinling Tan; Ming Li; Fuquan Hu
Journal:  Curr Microbiol       Date:  2013-01-18       Impact factor: 2.188

8.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Antibacterial efficacy of temperate phage-mediated inhibition of bacterial group motilities.

Authors:  In-Young Chung; Nuri Sim; You-Hee Cho
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

10.  Bacteriophage-based synthetic biology for the study of infectious diseases.

Authors:  Robert J Citorik; Mark Mimee; Timothy K Lu
Journal:  Curr Opin Microbiol       Date:  2014-07-03       Impact factor: 7.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.